This page shows the latest loss of exclusivity news and features for those working in and with pharma, biotech and healthcare.
when it came to keeping patients in work without loss of productivity caused by the skin disorder. ... The prospects for risankizumab and upadacitinib matter for AbbVie because it’s well-recognised that the loss of exclusivity for Humira after 2022 in
Biosimilar companies are now gearing up to pounce on AbbVie’s inflammation blockbuster Humira (adalimumab) when it loses its patent exclusivity across Europe on 16 October. ... As the potential savings are so great, NHS England’s Commercial Medicines
Its consumer health division will become a standalone unit after lack of buyer interest. ... the loss of market exclusivity for older, big-selling drugs.
This is most immediately obvious in the first - the threat of lost reputation. ... This beneficial combination of factors seems to be changing however. Profit streams erode quickly with loss of exclusivity of blockbusters and even patented products face
Branded medication continues to get prescribed even after loss of exclusivity. ... In the pharma sector specifically, we know branded medication continues to get prescribed even after loss of exclusivity.
Contraction in economies, pressure on pharmaceutical prices, increasing competitive pressure, and loss of marketing exclusivity on major products drove the need for more accurate planning and forecasting. ... One key driver of uncertainty is the loss of
More from news
Approximately 0 fully matching, plus 52 partially matching documents found.
The loss of exclusivity for Lipitor continued to have a major impact, but alongside this, a further 24 of its therapies suffered a drop in sales. ... in an attempt to mirror the success of Roche and its Genentech subsidiary.”.
Loss of exclusivity on some of its leading brands - not least Lipitor - contributed to an overall dip in revenue of more than $6.5bn from 2011. ... In fact, patent expiry was an industry-wide epidemic in 2011/12, with loss of exclusivity plaguing many of
Major products were about to lose, or had just lost, their patent exclusivity.”. ... For Nycomed this meant loss of exclusivity (LOE) on its blockbuster gastroinestinal drug pantoprazole and the consequent need to reorganise its business.
Appropriate patients. Payers want predictability of patient outcomes and certainty of budget impact. ... Market access is everyone's responsibility throughout the life of the medicine from early phase R&D right through to loss of exclusivity. .
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
4. It’s no wonder “loss of exclusivity (LOE)” or “the patent cliff” is an ominous prospect for drug manufacturers – shrouded in the threat of job losses and falling share prices. ... Loss of exclusivity (LOE) is a natural milestone in a
As a Publicis Health company, Langland has first-hand experience of the value of working as one team. ... Simplifying client access to talent builds on Publicis Groupe’s philosophy: The Power of One - ensuring continuous access to expertise and
Since its inception in 2003, Two Labs has led 215+ new product launches and more than 300+ in-market projects from pre-launch to loss of exclusivity. ... For further information:. Jessica Krauser. VP of Marketing. Two Labs. Email:
pharmaceutical industry probably experiences more of this type of activity than most others. ... Whether you’re dealing with a merger, a disruptive new competitor, loss of exclusivity, or preparing for launch, contact Bedrock to discuss navigating
Price decay after loss of brand exclusivity”. These are just three headlines that come up when you Google “drug patent expiry”. It’s no wonder “loss of exclusivity (LOE)” or “the ... Loss of exclusivity (LOE) is a natural milestone in a
More from PMHub
Approximately 1 fully matching, plus 9 partially matching documents found.
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...